Figure 4. Western blot analysis of VEGF-A_165b expression in the glaucomatous retina. A: VEGF-A_165b expression following five days of elevated IOP. Retinal VEGF-A_165b monomer and dimer were detected at 22.5 and 45 kDa, respectively. B: Glaucomatous/control ratio of normalized VEGF-A_165b densitometry readings in the retina following five days of elevated IOP. Expression of the 22.5 kDa VEGF-A_165b was increased significantly in the glaucomatous retinas compared to the controls. C: VEGF-A_165b expression following 10 days of elevated IOP. VEGF-A_165b monomer and dimer were observed at 22.5 and 45 kDa in the retina, respectively. D: Glaucomatous/control ratio of normalized VEGF-A_165b densitometry readings in the retina following 10 days of elevated IOP. Both 22.5 kDa and 45 kDa VEGF-A_165b were expressed at comparable levels in the control and glaucomatous retinas. The positive control was the brain while the negative control was VEGF-A₁₆₄ recombinant protein. The loading control was α-tubulin.